Treatment Resistant Depression Study

The Mind Body Program, in the Emory University Department of Psychiatry and Behavioral Sciences, is conducting a clinical research study to assess the effectiveness of a medication in patients with treatment resistant depression. In this study, patients will receive either infliximab (Remicade®) or placebo (normal saline) infusions for difficult to treat depression. Infliximab (Remicade®) is FDA approved to treat rheumatoid arthritis and Crohn’s disease but has not been studied in the treatment of depression.

To qualify for this study you must:

• Be between 25-60 years old
• Have been diagnosed with major depression and be currently depressed
• Have been unsuccessfully treated with antidepressant medications
• Be medically healthy

You will not qualify if you:

• Have been treated with infliximab (Remicade®), etanercept or adalimimub
• Have a history of tuberculosis or an autoimmune disorder
• Are pregnant, nursing, or planning pregnancy in the next year

What will be expected of you if you participate?

• Provide informed consent
• Discuss psychiatric and medical history
• Have physical exams, ECG, chest x-ray, TB tests and blood draws at no expense to you
• Visit Emory University 9 times over 12 weeks. Two study visits include optional overnight stays in the Emory Hospital research unit

Compensation:

Participants will be compensated for time and travel expenses.  Tokens will be provided for visitor parking.

If you are interested in this study and would like more information, please contact us by phone (404-727-8229) or e-mail (mindbody@emory.edu) or complete the following form.